Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer
Metrics: PDF 3930 views | HTML 3398 views | ?
Xiaomin Liu1,*, Ping Wang1,*, Caiyan Zhang1 and Zhongliang Ma1
1Lab for Noncoding RNA and Cancer, School of Life Sciences, Shanghai University, 200444 Shanghai, China
*These authors contributed equally to this work
Zhongliang Ma, email: firstname.lastname@example.org
Keywords: epidermal growth factor receptor (EGFR), noncoding RNA, precision medicine, lung cancer
Received: October 11, 2016 Accepted: March 24, 2017 Published: April 05, 2017
Lung cancer is a leading cause of cancer mortality worldwide. In tumors, the important role of noncoding RNA regulatory networks has been more and more reveal. EGFR has been identified as an oncogenic driver of NSCLC, especially activating mutations EGFR and its inhibition with specific TKIs can generate dramatic tumor responses. Studies have shown that EGFR plays significant roles in the progression of NSCLC. Subset analysis of the small proportion of patients with EGFR-mutant lung cancer showed a disease-free survival benefit, but was underpowered to detect a survival advantage. Herein, we highlight the progression of EGFR, noncoding RNA, and their roles in carcinogenesis. We also focus on anti-lung cancer drug development and EGFR-related drug resistance.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.